logo
Plus   Neg
Share
Email

Sanofi : FDA Accepts Dupixent For Review In Children With Moderate-to-severe Asthma

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application or sBLA for Dupixent or dupilumab as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.

The submission was supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial.

The companies noted that the acceptance represents another milestone in the development of Dupixent in addressing diseases driven by type 2 inflammation.

Dupixent is currently approved as an add-on treatment for patients with uncontrolled moderate-to-severe asthma aged 12 and older with elevated eosinophils or oral corticosteroid dependent asthma.

The target action date for the FDA decision is October 21, 2021 and the European Union regulatory submission for children aged 6 to 11 years with asthma is planned for the first-quarter 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online. Alcoa Corp. (AA), the largest producer of aluminum in the US, Thursday reported a first-quarter profit that more than doubled from a year ago, driven by increased shipments and prices. Both adjusted earnings and revenues for the quarter trumped Wall Street analysts' estimates. Pittsburgh-based Alcoa... Walmart expects two-thirds of their Walmart U.S. hourly store roles to become full-time by the end of the current fiscal year, with consistent schedules from week to week, as part of their focus on creating even more opportunity for associates at Walmart.
Follow RTT